OBJECTIVE: To assess the predictive and prognostic value of progressive metabolic disease (PMD) by the use of early 18Fluorodeoxyglucose positron emission tomography (18FDG-PET) in patients with clinical stage IV non-small cell lung cancer (NSCLC) treated with first-line chemotherapy. METHODS: An 18FDG-PET performed following the first cycle of chemotherapy (PET-1) was compared with a pretreatment 18FDG-PET (PET-0) and a computed tomography (CT) scan after the third cycle (CT-3). The primary endpoint was the positive predictive value (PPV) of PMD. Secondary endpoints included the prognostic value of PMD. RESULTS: Eleven of 38 patients (29%) had a PMD by PET-1, and 15 (39%), including all patients with a PMD, experienced a progressive disease by CT-3. The PPV of PMD was 100% according to both the European Organization for Research and Treatment of Cancer (EORTC) criteria and the PET Response Criteria In Solid Tumors (PERCIST) (p value for both, <0.0001). Patients with a PMD by PET-1 had a median overall survival of 7.0 months versus 14.0 months for those without a PMD (p = 0.04, according to the EORTC criteria). CONCLUSIONS: Early 18FDG-PET assessment deserves further investigation for the identification of NSCLC patients who do not benefit from first-line chemotherapy.
OBJECTIVE: To assess the predictive and prognostic value of progressive metabolic disease (PMD) by the use of early 18Fluorodeoxyglucose positron emission tomography (18FDG-PET) in patients with clinical stage IV non-small cell lung cancer (NSCLC) treated with first-line chemotherapy. METHODS: An 18FDG-PET performed following the first cycle of chemotherapy (PET-1) was compared with a pretreatment 18FDG-PET (PET-0) and a computed tomography (CT) scan after the third cycle (CT-3). The primary endpoint was the positive predictive value (PPV) of PMD. Secondary endpoints included the prognostic value of PMD. RESULTS: Eleven of 38 patients (29%) had a PMD by PET-1, and 15 (39%), including all patients with a PMD, experienced a progressive disease by CT-3. The PPV of PMD was 100% according to both the European Organization for Research and Treatment of Cancer (EORTC) criteria and the PET Response Criteria In Solid Tumors (PERCIST) (p value for both, <0.0001). Patients with a PMD by PET-1 had a median overall survival of 7.0 months versus 14.0 months for those without a PMD (p = 0.04, according to the EORTC criteria). CONCLUSIONS: Early 18FDG-PET assessment deserves further investigation for the identification of NSCLCpatients who do not benefit from first-line chemotherapy.
Authors: Albert Comelli; Samuel Bignardi; Alessandro Stefano; Giorgio Russo; Maria Gabriella Sabini; Massimo Ippolito; Anthony Yezzi Journal: Comput Biol Med Date: 2020-03-16 Impact factor: 4.589
Authors: Janna E van Timmeren; Sara Carvalho; Ralph T H Leijenaar; Esther G C Troost; Wouter van Elmpt; Dirk de Ruysscher; Jean-Pierre Muratet; Fabrice Denis; Tanja Schimek-Jasch; Ursula Nestle; Arthur Jochems; Henry C Woodruff; Cary Oberije; Philippe Lambin Journal: PLoS One Date: 2019-06-03 Impact factor: 3.240
Authors: Giuseppe Luigi Banna; Timothée Olivier; Francesco Rundo; Umberto Malapelle; Filippo Fraggetta; Massimo Libra; Alfredo Addeo Journal: Front Med (Lausanne) Date: 2019-07-31
Authors: Sara Elena Rebuzzi; Alessio Signori; Marco Stellato; Daniele Santini; Marco Maruzzo; Ugo De Giorgi; Paolo Pedrazzoli; Luca Galli; Paolo Andrea Zucali; Emanuela Fantinel; Claudia Carella; Giuseppe Procopio; Michele Milella; Francesco Boccardo; Lucia Fratino; Roberto Sabbatini; Riccardo Ricotta; Stefano Panni; Francesco Massari; Mariella Sorarù; Matteo Santoni; Alessio Cortellini; Veronica Prati; Hector Josè Soto Parra; Francesco Atzori; Marilena Di Napoli; Orazio Caffo; Marco Messina; Franco Morelli; Giuseppe Prati; Franco Nolè; Francesca Vignani; Alessia Cavo; Giandomenico Roviello; Miguel Angel Llaja Obispo; Camillo Porta; Sebastiano Buti; Giuseppe Fornarini; Giuseppe Luigi Banna Journal: Front Oncol Date: 2022-09-23 Impact factor: 5.738